Peter Ordentlich - 15 Feb 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Scientific Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
15 Feb 2023
Net transactions value
-$1,118,394
Form type
4
Filing time
17 Feb 2023, 17:09:58 UTC
Previous filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $48,309 +7,572 $6.38 7,572 15 Feb 2023 Direct
transaction SNDX Common Stock Sale $195,688 -7,572 -100% $25.84 0 15 Feb 2023 Direct F1, F2
transaction SNDX Common Stock Options Exercise $125,482 +17,428 $7.20 17,428 15 Feb 2023 Direct
transaction SNDX Common Stock Sale $450,404 -17,428 -100% $25.84 0 15 Feb 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $450,404 -17,428 -100% $25.84 0 15 Feb 2023 Common Stock 17,428 $7.20 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $195,688 -7,572 -100% $25.84 0 15 Feb 2023 Common Stock 7,572 $6.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 443,841 options to purchase shares of common stock that are vested and immediately exercisable and a total of 202,500 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $25.53 to $26.10.
F3 This option is fully vested.